Page contents Key factsDecisionKey facts Active Substance Avadomide Therapeutic area Oncology Decision number P/0379/2018 PIP number EMEA-002405-PIP01-18 Pharmaceutical form(s) Capsule, hard Condition(s) / indication(s) Treatment of mature B-cell neoplasms Route(s) of administration Oral use Contact for public enquiries Celgene Europe LimitedTel. +41 327298500E-mail: medinfo.intl@celgene.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 07/12/2018DecisionP/0379/2018: EMA decision of 7 December 2018 on the granting of a product specific waiver for avadomide (EMEA-002405-PIP01-18)AdoptedReference Number: EMA/812160/2018 English (EN) (180.33 KB - PDF)First published: 13/02/2019ViewShare this page